



# PRESENTED ABSTRACTS & POSTERS

## The 34th Annual San Antonio Breast Cancer Symposium

December 6-10, 2011 • San Antonio, TX • Henry B. Gonzalez Convention Center

### Wednesday, December 7, 2011

**2:45 p.m. - 3:00 p.m.**

**Location:** Exhibit Hall D

**General Session 2:**

Program #S2-3 (Oral)

NSABP protocol B-34: A clinical trial comparing adjuvant clodronate vs. placebo in early stage breast cancer patients receiving systemic chemotherapy and/or tamoxifen or no therapy - final analysis.

**Contributors:**

Paterson AHG, Anderson SJ, Lembersky BC, Fehrenbacher L, Falkson CI, King KM, Weir LM, Brufsky AM, Dakhil S, Lad T, Baez-Diaz L, Gralow JR, Robidoux A, Perez EA, Zheng P, Geyer CE, Swain SM, Costantino JP, Mamounas EP, Wolmark N

**5:00 p.m. - 7:00 p.m.**

**Location:** Exhibit Halls A-B

**Poster Session 1:**

Response Predictions - I  
Program #P1-06-15

A genomic predictor developed from breast cancer cell lines predicts both disease-free survival and overall survival in breast cancer patients treated with doxorubicin and cyclophosphamide: A collaborative project of the NSABP and Precision Therapeutics.

**Contributors:**

Shen K, Tang C, Kim C, Pogue-Geile K, Anderson SJ, Costantino JP, Bear HD, Song N, Tian C, Gabrin MJ, Zhang Y, Geyer Jr. CE, Wolmark N

**5:00 p.m. - 7:00 p.m.**

**Location:** Exhibit Hall B

**Ongoing Trials Poster Session 1:**  
HER2- Program #OT1-02-07

NSABP B-47: A randomized phase III trial of adjuvant therapy comparing chemotherapy alone (six cycles of docetaxel plus cyclophosphamide or four cycles of doxorubicin plus cyclophosphamide followed by weekly paclitaxel) to chemotherapy plus trastuzumab in women with node-positive or high-risk node-negative HER2-low invasive breast cancer.

**Contributors:**

Fehrenbacher L, Jeong JH, Rastogi P, Geyer CE, Paik S, Ganz PA, Land SR, Costantino JP, Swain SM, Mamounas EP, Wolmark N

**5:00 p.m. - 7:00 p.m.**

**Location:** Exhibit Hall B

**Ongoing Trials Poster Session 1:**  
HER2- Program #OT1-02-05

A phase III clinical trial comparing trastuzumab given concurrently with radiation therapy to radiation therapy alone for women with HER2-positive DCIS resected by lumpectomy: NSABP B-43.

**Contributors:**

Julian TB, Anderson SJ, Cobleigh MA, Siziopikou KP, Arthur CW, Zheng P, Mamounas EP, Pajon ER, Behrens RJ, Chu L, Leasure NC, Atkins JN, Polikoff J, Seay TE, McCaskill-Stevens WJ, Rabinovitch R, Wolmark N

### Thursday, December 8, 2011

**5:15 p.m. - 7:00 p.m.**

**Location:** Exhibit Halls A-B

**Poster Session 3:**

Treatment - Local - Radiotherapy  
Program #P3-13-01

Boost radiation therapy not of value in reducing IBTR of invasive or noninvasive breast cancers for patients with DCIS: Results from the NSABP B-24 trial.

**Contributors:**

Julian TB, Vicini FA, Costantino JP, Arthur DW, Kidwell KM, Land SR, Mamounas EP, Wolmark N

**5:00 p.m. - 7:00 p.m.**

**Location:** Exhibit Hall B

**Ongoing Trials Poster Session 2:**

Radiotherapy  
Program #OT2-06-02

A randomized phase III study of conventional whole breast irradiation vs partial breast irradiation for women with stage 0, 1, or 2 breast cancer: NSABP B-39/ RTOG 0413.

**Contributors:**

Julian TB, Costantino JP, Vicini FA, White JR, Cecchini RS, Winter KA, Arthur DW, Kuske R, Rabinovitch R, Parda DS, Mamounas EP, Curran Jr. WJ, Wolmark N

### Friday, December 9, 2011

**7:00 a.m. - 9:00 a.m.**

**Location:** Ballroom A

**Poster Discussion 7:**

What's New In Chemotherapy Trials?

Viewing - 7:00 a.m.  
Discussion - 7:45 a.m.  
Program #PD07-08

The effect on surgical complications of bevacizumab added to neoadjuvant chemotherapy: NSABP Protocol B-40.

**Contributors:**

Bear HD, Tang C, Rastogi P, Geyer CE, Robidoux A, Atkins JN, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, Pajon ER, Senecal FM, Gaur R, Margolese RC, Adams PT, Gross HM, Costantino JP, Swain SM, Mamounas EP,